Сведения
о ведущей организации по диссертации Шиловой Ольги Николаевны
«Создание адресных противораковых агентов на основе ERBB2-специфичного белка DARPin 9-29»,
представленной на соискание ученой степени
кандидата биологических наук по специальности 03.01.03 – «молекулярная биология»

Полное и сокращенное наименование ведущей организации	Почтовый адрес, телефон, адрес электронной почты, адрес официального сайта в сети Интернет	Список основных публикаций сотрудников ведущей организации по теме диссертации в рецензируемых научных изданиях за последние 5 лет (не более 15 публикаций)
Федеральное государственное бюджетное учреждение науки Институт биологии гена Российской академии наук (ИБГ РАН)	Адрес: 119334, город Москва, улица Вавилова, дом 34/5 Телефон: +7 (499) 135-60-89 Факс: +7 (499) 135-41-05 E-mail: info@genebiology.ru	1. Slastnikova TA, Rozenkranz AA, Morozova NB, Vorontsova MS, Petriev VM, Lupanova TN, Ulasov AV, Zalutsky MR, Yakubovskaya RI, Sobolev AS. Preparation, cytotoxicity and vivo antitumor efficacy of 111In-labeled modular nanotransporters. Int J Nanomedicine. 2017. 12:395-410. 2. Sharapova TN, Romanova EA, Sashchenko LP, Yashin DV. Tilorone activates NK cells and cytotoxic lymphocytes that kill HLA-negative tumor cells. IUBMB Life. 2019. 71(3): 376-384. 3. Sharapova TN, Ivanova OK, Soshnikova NV, Romanova EA, Sashchenko LP, Yashin DV. Innate immunity protein Tag7 induces 3 distinct populations of cytotoxic cells that use different mechanisms to exhibit their antitumor activity on human leukocyte antigen-deficient cancer cells. J Innate Immun. 2017. 9(6): 598-608. 4. Kostina MB, Sass AV, Stukacheva EA, Korobko IV, Sverdlov ED. Enhanced vector design for cancer gene therapy with hierarchical enhancement of therapeutic transgene expression. 2017. Hum Gene Ther Methods. 2017 Oct;28(5):247-254.

subcellular delivery of anti-cancer agents. Front Pharmacol. 2019. 9:1577.
6. Rosenkranz AA, Slastnikova TA, Karmakova TA, Vorontsova MS, Morozova NB, Petriev VM, Abrosimov AS, Khramtsov YV, Lupanova TN, Ulasov AV, Yakubovskaya RI, Georgiev GP, Sobolev AS. Antitumor activity of Auger electron emitter 111In delivered by modular nanotransporter for treatment of bladder cancer with EGFR overexpression. Front Pharmacol. 2018. 9:1331.
7. Slastnikova TA, Ulasov AV, Rosenkranz AA, Sobolev AS. Targeted Intracellular Delivery of Antibodies: The State of the Art. Front Pharmacol. 2018. 9:1208.
8. Slastnikova TA, Rosenkranz AA, Khramtsov YV, Karyagina TS, Ovechko SA, Sobolev AS. Development and evaluation of a new modular nanotransporter for drug delivery into nuclei of pathological cells expressing folate receptors. Drug Des Devel Ther. 2017. 11:1315-1334.
9. Durymanov MO, Yarutkin AV, Bagrov DV, Klinov DV, Kedrov AV, Chemeris NK, Rosenkranz AA, Sobolev AS. Application of vasoactive and matrix-modifying drugs can improve polyplex delivery to tumors upon intravenous administration. J Control Release. 2016. 232:20-28.
10. Ivanova ES, Tatarskiy VV, Yastrebova MA, Khamidullina AI, Shunaev AV, Kalinina AA, Zeifman AA, Novikov FN, Dutikova YV, Chilov GG, Shtil AA. PF 114, a novel selective inhibitor of BCR ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells. Int J Oncol. 2019. 55(1):289-297.

		Korneev KV, Sviriaeva EN, Mazurov D, Schwartz AM, Kuprash DV. p63 and p73 repress CXCR5 chemokine receptor gene expression in p53-deficient MCF-7 breast cancer cells during genotoxic stress. Biochim Biophys Acta Gene Regul Mech. 2017. 1860(12):1169-1178. 12. Kantidze OL, Gurova KV, Studitsky VM, Razin SV. The 3D Genome as a Target for Anticancer Therapy. Trends Mol Med. 2019 Oct 31. pii: S1471-4914(19)30268-0. 13. Kantidze OL, Luzhin AV, Nizovtseva EV, Safina A, Valieva ME, Golov AK, Velichko AK, Lyubitelev AV, Feofanov AV, Gurova KV, Studitsky VM, Razin SV. The anti-cancer drugs curaxins target spatial genome organization. Nat Commun. 2019. 10(1):1441.

Ученый секретарь ИБГ РАН
д.б.н.

Набирочкина Е. Н.